Clinical trial
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
NCT00084084 · Shire, Industry · Completed
Key facts
| NCT number | NCT00084084 |
|---|---|
| Title | Replagal Enzyme Replacement Therapy for Children With Fabry Disease |
| Official title | An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | Agalsidase alfa |
| Enrollment | 17 |
| Start date | Jun 10, 2004 |
| Primary completion | Jun 15, 2011 |
| Completion | Jun 15, 2011 |
| First posted | Jun 7, 2004 |
| Last update posted | Jul 30, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: